Introduction
Since its introduction in 1977, coronary angioplasty has become an established technique for the treatment of atherosclerotic coronary disease. Currently, more than 500 000 procedures are performed each year worldwide. However, two major problems remain unresolved. The first, post-angioplasty acute vessel closure, occurs in about 5% of cases. In this setting, intracoronary stenting has been very useful for the management of postangioplasty dissections 1 ' 1 . The second problem, restenosis, occurs in 30 to 50% of cases. Thus far, drug therapy has shown little benefit in reducing the extent of this phenomenon. Recently, however, the STRESS trial showed that intracoronary stents could reduce restenosis rates from 42% to 32%, and the BENESTENT trial had an even greater reduction: from 32% to 22% [2>31 . The beneficial effect of stenting is presumably due to better vessel geometry since it induces more neointima formation than balloon angioplasty.
Balloon dilation causes vascular lesions, which include mechanical deformation, triple layer vessel injury and early thrombus formation. Mechanical injury initiates a complex process involving vasoactive hormones, growth factors, circulating cells and possibly blood lipids. The healing process is usually in three phases: thrombus formation, followed by smooth muscle cell activation and replication in the tunica media and probably in the adventitia' 4 ' 5 '. This is followed by intimal smooth muscle cell migration and proliferation, which precede matrix secretion' further coronary obstruction. The extent of smooth muscle cell proliferation, as assessed by proliferating cell nuclear antigen staining, varies between 1% and 20 ± 18% after vessel injury' 7 ' 81 . The exact timing of this cellular proliferation is unknown in humans, but in animal models it may last for about 4 weeks after stent implantation' 9 ' 101 . Schwartz et ai, using computer modelling, have estimated the peak post-angioplasty proliferative phase to be around 45 days in humans'" 1 . In addition to cell proliferation, elastic recoil and vascular remodelling have also been recognized as important mechanisms to explain the restenosis phenomenon' 12131 .
Until now, drug therapy has been focused on limiting cellular proliferation and/or thrombus inhibition. Although positive effects were reported in some animal models, they were not convincingly reproduced in humans. Recently, the use of glycoprotein Hb/IIIa inhibitors has been associated with a decrease in ischaemic complications and clinical restenosis after balloon angioplasty' 14 ' 151 . There is little doubt that thrombosis prevention after balloon injury represents a major issue for the future of coronary interventions.
Drug treatment has been shown to reduce neointima formation in animals but not humans. This has been attributed, in part, to differences in tissue drug concentrations between animals and man. Thus, local drug delivery has been advocated to prevent restenosis. New catheters delivering drugs locally or regionally after angioplasty have been designed and clinical trials are ongoing' 16 ' 171 . Our understanding of the molecular biology and genetics of the restenosis mechanism has also improved, but problems remain concerning safety, cost and the handling of these genetic tools' 181 .
Local radiation therapy has promise, but also drawbacks and possibly serious side effects. Radiation therapy has been part of our medical armamentarium for decades and its effectiveness in controlling actively dividing tumour cells is well established. The concept of Schwartz et a/.
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[27] using local radiation to control smooth muscle cell proliferation is based on the assumption that ionizing radiation will kill proliferating smooth muscle cells and therefore limit neointima formation. This therapy has been applied to benign situations such as prevention of cheloid scar, heterotopic bone formation or pterygium treatment as well as for the treatment of solid malignancies' 19 22] . Because of the biohazard, radiation therapy in clinical practice requires close collaboration between oncologists, physicists and technicians.
Brachytherapy is the term used to describe intracavitary or interstitial radiation therapy' 231 . Recently, this term has been used to describe endovascular radiation therapy from either radioactive sources or stents (see Appendix). We will review the current experience of using external or endovascular radiation therapy to reduce arterial neointima formation and we will try to delineate its potential therapeutic applications and possible limitations. (Table 1A and B) Gellman et al. first recorded angiographic results after single doses of external irradiation in rabbit iliac arteries after balloon injury'
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. At 28 days, the angiographic lumen diameter decrease was constant in the irradiated group. Schwartz et al. obtained similar results using over-expanded stents in pig coronary arteries, submitted to increasing doses of external radiation' 251 . Proliferative neointimal responses and lumen stenoses were seen in all groups, but tended to be exaggerated in the higher dose group (8 Gy) . In all three radiation groups, moderate to severe myocardial and adventitial fibrosis were present. Sudden death occurred in four irradiated pigs and all showed severe stenoses, consisting of organized neointima with fresh thrombus at the injury site. In contrast, Shefer et al. demonstrated a reduction in intimal formation after single exposure of a betairradiation source (9 Gy) applied against rabbit ear arteries after balloon injury'
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. They observed a maximum effect when irradiation was administered 2 days post injury but no effect when applied after 7 days. Abbas et al. studied angiographic and morphometric results 28 days after external irradiation with 6 or 12 Gy of rabbit iliac arteries after balloon angioplasty' 271 . Mean and minimal angiographic lumen diameters were decreased in all groups. However, in the 12 Gy treated group, lumen diameters at follow-up were not significantly different from initial values. There were minor differences in intimal hyperplasia between controls and the lower dose group. In contrast, less intimal proliferation was present in the 12 Gy treated group vs controls. Shimotakahara and Mayberg studied the effects of increasing doses and delayed administration of gamma-irradiation of rat carotid arteries'
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. All groups showed a reduction in the neointimal cross-sectional area when irradiated one day after balloon injury. Significant but less prominent reductions in neointimal area were noted for all doses in arteries irradiated 2 days after injury. Extending these results, Mayberg et al. performed a detailed dose ranging study and analysed the effect of timing of irradiation' 291 . Irradiation administered on day 1 after injury produced a significant dose-dependent reduction of intimal hyperplasia, with a 50% decrease at 5-7-5 Gy. In contrast, radiation treatment applied 3 or 5 days after injury showed significantly less inhibition of intimal hyperplasia. Thus, external beam radiation, when the dose level and timing were optimized for the model being treated, decreased post-angioplasty neointima formation. However, no significant reduction in neointima formation has been reported to date after external irradiation of stented segments' 25 -301 .
Endovascular high-dose rate irradiation therapy (Table 2A and B) Wiederman et al. studied the effects of 20 Gy delivered through an Iridium-192 ribbon to the pig coronary artery immediately before overstretch balloon angioplasty' 3 ' 1 . Each pig received a single dose delivered over 1 h. At 30 days, there was less intimal proliferation in the irradiated group but the medial layer of the vessel showed diffuse interstitial fibrosis. Overall, compared with control animals, pre-angioplasty intracoronary irradiation reduced the bulk of neointima proliferation by 71% and percent area stenosis by 63%. In a follow-up study performed at 180 ± 8 days, it was found that the benefit seen at 30 days had been maintained' 321 . In contrast, when using a dose of 10 Gy, they described a 123% increase in neointima formation as compared with controls' 331 . Addressing the long-term effect, these authors described diffuse interstitial fibrosis throughout the medial and adventitial layers'
331
. Intimal proliferation consisted of equal proportions of smooth muscle cells and zones of diffuse fibrosis. There was no ultrastructural evidence of malignant or pre-malignant transformation in any cell lines, and vessels distal to the irradiation site were intact. The same model was used for a study of the effects of gamma-irradiation (20 Gy) on vasomotor function, both acutely and later (32 days)' 34 '. Early, irradiated segments were vasoconstricted in response to acetylcholine and did not vasodilate after nitrate infusion. When studied later, the vasodilatory response to acetylcholine was found to be restored but loss of dilation after nitrates persisted. The endothelium was intact but the media throughout the irradiated segment was focally dependent and replaced by loose connective tissue, collagen and fibroblasts. Interestingly, some mild neointimal proliferation, albeit less than in control vessels, occurred eccentric to the vessel. As the ribbon was not centred in the vessel, this might suggest that the irradiation dose was not uniformly distributed throughout the length of the target vessel.
Mazur et al. studied the effects of intracoronary irradiation delivered through an Iridium-192 source connected with an afterloader'
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. After balloon overstretch and oversized stent injury, incremental doses from 10 Gy to 25 Gy were applied to pig coronary arteries. At 28 days, maximal intimal thickness was significantly reduced in the 15 Gy and 25 Gy treated groups. Of note, there was no beneficial effect at any dose in the stented right coronary segments. The absence of source centring and the constant bending of the right coronary artery were the main reasons advanced to explain the lack of efficacy' 35 '. Medial fibrosis was recognized in all groups, but the extent of adventitial fibrosis, haemorrhage and thrombus formation were radiation dose-dependent. Waksman et al. and Sarac et al., using gamma irradiation with slightly lower doses, confirmed these positive effects in pig and rat models and Waksman et al. showed an improved benefit when the same dose (7 Gy) was administered 2 days after injury' 36 ' 371 . A long-term beneficial effect was observed at 6 months, without any morphological differences in the media or adventitia being observed between the irradiated and control groups' 361 . The same investigators studied the effects of irradiation with iridium-192 or strontium-yttrium-90 prior to slotted tube stent implantation in porcine coronary arteries' 38 '. The dose was estimated at 14 Gy at a depth of 2 mm and exposure time lasted between 28-38 min for gamma irradiation and 192 s for beta-irradiation. At 28 days, irradiated stented arteries exhibited significantly less neointima formation than controls. Many segments showed inflammatory infiltrates surrounding the stent wires, but these were less extensive in the treated arteries compared to the control arteries. Wiederman et al. using a similar experimental model and a dose of 20 Gy prior to stent implantation but with a different stent design (coil) failed to confirm these positive effects' 39 '. Hehrlein et al., using an activated guide-wire failed to demonstrate a significant reduction in neointima formation after irradiation post stent implantation, although there was a positive trend' 40 '.
Verin et al. delivered intra-arterial radiation through pure Yttrium coils and a centring balloon catheter in hypercholesterolaemic rabbits' 41 '. Using doses from 6 to 18 Gy, they treated carotid and iliac arteries after de-endothelialization and dilation. At 8 days, all irradiated groups showed a decreased number of neointima cells. However, at 6 weeks, percent area stenosis and mean number of neointimal cell layers were significantly reduced only in the group with 18Gy irradiation. Waksman et al., using a similar pure beta-source, performed a range of dose studies in pig Hehrlein et a/. [40] Verin et a/.' Wiedermann et a/. 13 Hehrlein et a/. 1401 Verin et a/. Hehrlein et a/.
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Carter et a/. Radioactive stents (Table 3A and B) Hehrlein et al. described the first intra-arterial use of radioactive stents produced by particle bombardment in a cyclotron'
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. Activated stents were created, emitting gamma and beta isotopes of half-lives up to 2-7 years. Three series of stents of increasing radioactivities from 3-9 |iCurie to 35 uCurie were produced. At 4 weeks, exposure to the two higher dose levels caused a significant reduction in neointima formation, while in all three groups there was a significant reduction in proliferating cell nuclear antigen positive cells (16% in non-radioactive stents vs 0-8% in 35 uCi stents) and smooth muscle cell counts (705 ± 23 SMCs/0-1 mm 2 in non-radioactive stents vs 229 ± 9 SMCs/01 mm 2 in the 35 uCi activity group). This reduction was maintained over a year. These authors also assessed vascular reendothelialization, which occurred despite prolonged irradiation. After a week, arteries with non-radioactive stents began to endothelialize but the process was delayed in a dose-dependent fashion in vessels with radioactive stents. Endothelial cell coverage of nonradioactive stents was completed within 4 weeks, while 12 weeks were required for >95% endothelialization in the group with the highest activity stent. After 4 weeks, the collagen content had increased in the lowest activity group and was more pronounced in the two higher activity groups. Again this was maintained over one year. The exact significance of this collagen accumulation is unknown, but it could result from growth factor release associated with prolonged irradiation exposure.
Laird et al. studied the effects of Strecker stents, ion-implanted with 31 P beneath the surface, in porcine iliac arteries' 441 . Stents were made radioactive by exposure for several hours to a neutron flux which converted about 1/100 000 3I P atoms to 32 P and generated other radioisotopes estimated to be short-lived. Twenty-eight days' exposure to radioactive stents with an initial activity of 0014 ucurie caused a significant reduction in neointimal area (37%) and percent area stenosis (32%) compared to the effects of control nonradioactive stents. There was no difference between the two groups in terms of smooth muscle cell proliferation as assessed by the proliferating cell nuclear antigen technique. Scanning electron microscopy showed complete endothelialization of arteries with control and radioactive stents except at the proximal and distal ends of the stents. 32 P, produced by neutron bombardment, was ionized and ion-implanted beneath the outer surface of titanium-nickel stents using a specially designed reactor. 32 P emitting stents with 4 and Ducurie as initial activities, were implanted in rabbit iliac arteries and histomorphometry was performed at 4 and 12 weeks'
451
. At 4 weeks, both groups showed significant reductions in neointima formation and in smooth muscle cell density. Twelve weeks after implantation, only the group receiving the highest radiation dose showed a significant reduction in neointima formation and in smooth muscle cell density compared with non-radioactive stents. Neointima formation appears to have been only delayed in the low dose group. Endothelial cell coverage was present after 4 weeks, in all groups albeit less complete in arteries implanted with radioactive stents.
Recently, Carter et al., using a similar radioactive stent, studied responses to 01 to 23 ucurie stents' 461 . Neointima formation was reduced with low (0-15-0-5 uCi) activity and high (3-23 uCi) activity stents, but increased neointima formation was observed with stents of 1 uCi initial activity. This highlights the complexity of the response of organized tissues such as the vascular system to ionizing radiations.
Human experience with endovascular radiation (Table 4) The Frankfurt group reported the use of endovascular high-dose rate brachytherapy for recurrent stenosis or occlusion in stented femoral arteries'
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. Because of fear of radiation-induced malignancy, only patients older than 65 years were selected. The procedures were started in the radiology department where a 9 Fr catheter was placed at the stent site. A 5 Fr applicator was then carefully positioned inside the catheter and fixed. The patients were transferred to the radiotherapy unit and the applicator was connected to an Iridium-192 afterloading machine. The average dose was 12Gy at 3 mm depth delivered in about 200 s (48] . All . In the group with 20 Gy, four out of 12 treated arteries developed restenosis. The occurrence of these coronary aneurysms is certainly alarming but later re-calculation of the administered doses found significant discrepancies and raised the possibility that doses up to 50 Gy had in fact been given in a short time'
531
. The Geneva group, using a centring balloon and beta-radiation with Yttrium, performed a feasibility trial in 15 patients using a target dose of 18 Gy to the inner vessel wall' 
Summary of the unresolved issues A. Mechanisms of action
Ionizing radiations have a number of effects on target cells, the most obvious of which is cell killing 1601 . For highly differentiated cells which do not divide (neurons or secretory cells), cell death is defined as a loss of specific function and in general, a very high radiation dose (approximately 100 Gy) is required to kill cells in a non-proliferating system. For proliferating cells, cell death occurs at a much lower dose and there is strong evidence that the nucleus, specifically DNA, is the principal target for radiation-induced cell lethality' 611 . There is an inverse relationship between cell survival and the number of lethal, asymmetrical exchange type chromosome aberrations observed per cell. When the cell divides, chromosome abnormalities induced earlier by radiation may be so severe as to prevent completion of division. Other cells may divide successfully and even complete several cycles before dying during subsequent mitosis due to the cumulative effects of chromosome damage. Radiation damage not expressed as lethal changes may result in mutagenic and carcinogenic changes in the descendants of irradiated cells. A number of biological factors influence cell survival, the most important of which in the context of this review is repair of sub-lethal damage. This process reflects the repair of DNA damage which may take place before interactions between damaged sites can produce lethal chromosome aberrations. As a result, low-dose rate or fractional radiation causes less cell killing because sublethal damage can be repaired between dose fractions or during prolonged radiation exposure' 62 '. Fractionation is an integral part of clinical radiation treatment practice, largely because it reduces the severity of normal tissue damage. Fractionated intravascular radiation therapy would be an unrealistic approach in the prevention of coronary restenosis.
In addition to reproductive cell death, ionizing radiation may induce programmed cell death or apoptosis in normal tissue and in tumours. Apoptosis is activated by a specific signal which initiates a cascade of biochemical and morphological events culminating in cell death. It occurs in a number of situations during normal development and can also be induced by cytotoxic drugs and radiation' 631 . However, the effect of radiation-induced apoptosis on the overall radiation response of normal tissues and tumour is still unclear' 641 . It has recently become apparent that cell killing, whether the result of reproductive death or by apoptosis is not the sole reason for the derangement of function observed in organized tissues following radiation. Radiation can result in the induction of early and late response genes, and the gene products, specifically cytokines and growth factors may influence the radiation response of the tissue' 651 . Experimental findings indicate that growth factors are synthesized de novo and secreted by cells which survive irradiation' 661 . Growth factor-like molecules can promote proliferation of smooth muscle cells and participate in abnormal proliferation of endothelial cells and the initiation of fibrosis characteristic of late radiation response. Therefore, similarities exist between radiation-induced late responses and restenosis which partly involves abnormal proliferation of smooth muscle cells after vessel injury.
Control of restenosis by vascular irradiation is based on the simple premise that the target population, proliferating smooth muscle cells, can be eliminated or controlled by radiation. Simple calculations based on the size of the population suggest that single doses required to do so would probably be unacceptably large because of the risks of late complications' 671 . The risks associated with high radiation dose could be offset to some extent by localizing the radiation to the target population and/or by reduction of dose rate. The radiation doses which would not exceed normal tissue tolerance might be expected, based on the radiobiology and cell kinetics, to cause delay in restenosis but not elimination of the process, at least if smooth muscle cells continue to proliferate at the same rate indefinitely'
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. As yet unexamined mechanisms which might influence this response would be the withdrawal or reduction of the factors which stimulate proliferation of smooth muscle cells and the possibility that these smooth muscle cells which normally divide very slowly will reach the limit of their capacity to undergo further division. In that context, endothelial regeneration is probably a key . [68] issue 1 
B. Gamma or Beta irradiation
Beta particles have the same characteristics as electrons which have a limited tissue depth penetration. When they are slowed down by nuclei interactions, they give rise to high penetration X-rays, called bremsstrahlung' 691 . Because the mass of tissue involved in the restenotic process is on a millimetre scale, it seems appropriate to favour beta-radiation. The range of gamma-radiation and X-rays is usually greater than that of ^-particles and strict radioprotective measures are required. It should not be concluded, however, that manipulation of beta-emitters does not require special attention. Depending on the energy, /?-particles can travel a significant distance through air, and therefore, precautions are required to limit the risks of source escape. In addition, secondary X-ray emission after ionization by beta rays is proportional to the atomic number of the interacting matter and covers the entire energy spectrum of the beta isotope. For example, bremsstrahlung of yttrium will generate a few X-rays with a mean energy of 300 Kev and a maximum energy of 2-3 Mev' 70) . Lead shielding (high atomic number), commonly used to stop gamma radiation or X-rays, is not appropriate for /? radioprotection and therefore lucite or plastic (low atomic number) protectors are also required. Moreover, during the procedure secondary emission resulting from interactions of beta-rays and the patient's body will result in scattered radiation. Waksman et al. compared the total effective body dose to the patient using gamma and beta irradiation' 421 . Using a delivered target dose of 14 Gy at 2 mm depth (in 30 min with Irl92 source and 4 min with St/Yt 90), the body dose was estimated at 019 mSievert (mSv) for the beta emitter and 100 mSv for the gamma emitter. In contrast, it has been estimated that a patient receives a total effective dose of about 20 mSv per angioplasty procedure 171] . By comparison, a thallium scan (100 MBq) will give a patient dose of 25 mSv and a Mibi scan (1110 MBq), a dose of 9 mSv' 71 '. Johns et al. have also estimated the total effective dose received by the cardiologist and the scrub nurse during angioplasty procedure at the Montreal Heart Institute. On average, a cardiologist receives 0003 mSv per procedure, to give an annual dose of 1-7 mSv, while the nurse receives 0-9 mSv/year [721 . In contrast, the cardiologist during a brachytherapy procedure with St/Yttrium, which delivers a target dose of 14 Gy at 2 mm depth, will receive a dose of 0-009 mSv' 42 '. Therefore, the cardiologist will receive a total dose four times higher than usually received for a standard balloon angioplasty. Nevertheless, these doses remain below the maximal permissible effective personal dose of 20 mSv/year set by the International Commission of Radiation Protection (ICRP) [731 . However, it should be remembered that no dose of radiation is known to be safe and the ICRP has thus recommended adoption of the ALARA (As Low As Reasonably Achievable) principle in order to limit radiation exposure to workers' 741 . 43 '. As already discussed, gene induction could be responsible for the dual reaction observed after vascular irradiation' 651 . For example, TGF-/?, which is thought to play a role in matrix secretion during restenosis, is released from mesangial cells after ionizing radiation exposure and could also affect the radiation response of adjacent cells' 75 ' 761 . These factors complicate prediction of the optimal dose of ionizing radiation to reduce smooth muscle cell proliferation, and the effects on the other vascular cells remain to be determined. In addition, the timing of the radiation delivery, as described in a previous section, is also important. Recently, Waksman et al. were unable to reproduce positive results when the radiation dose was administered after stent implantation' 77 '.
C. Administered doses
D. High dose rate vs low dose rate
Catheters and radioactive stents deliver radiations at different dose rates. Catheter studies employing or St/Yt-90 delivered the dose between 3 min and 1 h, and dose rates varied from 0-23 to 6-67 Gy . min '. With X-rays and gamma-rays, the dose-rate effect is an important parameter determining the biological consequences of the absorbed dose' 62 '. As a rule in radiobiology, the biological effect of a given dose is lowered if the dose-rate is reduced and the overall exposure time is increased' 62 '. The dose rate effect is significant between 0-1 Gy . h ~' and several Gy . min ~ '. Above and below that range, differences in response for different dose rates are negligible. The magnitude of the dose-rate effect varies dramatically among different types of cells and between species. Comparing different human cell lines in culture, Hall et al. showed that differences in dose response for different cell lines was greatest at low dose rates. At high dose rates, there is a moderate effect due to variations in intrinsic cell radiosensitivities, whereas at lower dose rates, there is a wider range of response since different cell lines repair sublethal damage to different degrees' 78 '. This observation is important to keep in mind when speculating about the late effects of endovascular radiation therapy. Dose-rates responses could be ultimately an important factor determining which technology between catheter-based endovascular brachytherapy (high-dose rate) and radioactive stent (low-dose rate) would offer the best therapeutic ratio.
E. Delayed effects
Potential adverse effects are essential to keep in mind when one considers the use of endovascular ionizing radiations. Restenosis is not, in the majority of cases, a life-threatening condition and therefore the treatment itself should not carry a significant risk to the patient and the hospital staff. Ionizing radiations produce DNA damage resulting in cell death, mutagenetic and carcinogenetic changes. However, carcinogenesis is a multistage process and probabilities are sufficiently low to consider the risk as negligible after endovascular radiation. The cell depletion effect, which paradoxically may ultimately lead to excess cell proliferation, could be more of a problem' 23 ' . After angioplasty, however, smooth muscle cells from the media de-differentiate, migrate and proliferate. It is hypothesized that the acute killing effect of radiation would limit smooth muscle proliferation in the neointima. However, radiation affects all cells of the vascular wall and late effects could be related to the delayed depletion of some cells (adventitial cells, fibroblasts) with subsequent overshoot of re-population' 82 '. Smooth muscle cells from the media could be progressively replaced by fibroblasts and extracellular matrix (fibrosis) and progressive cellular depletion of the vascular wall could lead to aneurysm formation. Wiederman et al. studied pig coronary arteries 6 months after a delivered dose of 20 Gy and described fibrosis and loose interconnective tissue in the media and in the adventitia . No fibrosis or coronary aneurysms have been described to date after radioactive stent implantation. This could be due in part to the sparing effect of low-dose rates which tend to limit the adverse side effects of normal tissue irradiation. Nevertheless, delayed fibrosis is probably the most important side effect which should be excluded in order to consider endovascular radiation as a possible treatment modality for restenosis.
Conclusion
Endovascular irradiation represents a new field of investigation for the cardiologist. Obviously, endovascular brachytherapy will require intense collaboration between radiobiologists, oncologists, physicists and interventional cardiologists before being an approved therapeutic option. If the potential has already been demonstrated, many questions remain unanswered, such as optimal dose, timing of delivery, best device (catheter-high-dose rate vs stent-low-dose rate) and long-term effects. In the present state of knowledge, these unanswered questions require more experimental work before endovascular brachytherapy could be routinely applied to human patients for the prevention of coronary restenosis. Nevertheless, as some pathophysiological links seem to exist between cancer, atherosclerosis and perhaps restenosis, it is possible that careful analysis of the radiation effects on vascular cells in the context of restenosis prevention will provide new insight into these clinical syndromes' 
